# An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

> **NCT07378579** · PHASE1 · COMPLETED · sponsor: **Alumis Inc** · enrollment: 52 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ESK-001
- **DRUG:** Moxifloxacin (400 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07378579
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-21
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07378579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07378579, "An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07378579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*